Compugen to Participate in BTIG Biotechnology Conference 2026

Rhea-AI Summary

Compugen (NASDAQ/TASE: CGEN), a clinical-stage cancer immunotherapy company, announced that management will present and hold 1x1 meetings at the BTIG Biotechnology Conference 2026, taking place virtually from July 28-29, 2026. Investors are invited to contact their BTIG representative to request a meeting, and no replay will be available.

According to Compugen, its pipeline includes COM701, currently in a randomized ovarian cancer maintenance trial; rilvegostomig, a PD-1/TIGIT bispecific antibody developed by AstraZeneca under an exclusive license; and GS-0321, licensed to Gilead and in a Phase 1 trial conducted by Compugen.

News Market Reaction – CGEN

+6.41%

8 alerts

+6.41% Session close to close

+3.3% Peak in 4 hr 8 min

$224.17M Market Cap

0.9x Rel. Volume

In the Jul 21 session, CGEN gained 6.41%, reflecting a notable positive market reaction. Argus tracked a peak move of +3.3% during that session. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved +6.4% in the session following this news. The comparable ESMO poster announcement pr...

Analysis

The stock moved +6.4% in the session following this news. The comparable ESMO poster announcement produced a 4.08% 24-hour reaction, providing historical context for another investor-facing presentation. CGEN also had an active F-3 shelf, while recent insider activity was net selling.

Key Figures

Conference date: July 28-29, 2026 Meeting format: 1x1 meetings Rilvegostomig development: Phase 3, Phase 2 and Phase 1 clinical trials +1 more

4 metrics

Conference date July 28-29, 2026 BTIG Biotechnology Conference 2026

Meeting format 1x1 meetings BTIG Biotechnology Conference 2026

Rilvegostomig development Phase 3, Phase 2 and Phase 1 clinical trials AstraZeneca development program

GS-0321 trial phase Phase 1 clinical trial Compugen-conducted trial

Historical Context

5 past events · Latest: Jun 18 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Jun 18	Trial poster presentation	Neutral	+0.5%	MAIA-ovarian trial-in-progress poster presented at ESMO Gynaecological Cancers Congress.
Jun 11	Phase 1 poster presentation	Neutral	+4.1%	MAIA-Ovarian Phase 1 trial-in-progress poster scheduled for ESMO presentation.
Jun 08	AI/ML fireside chat	Neutral	-0.2%	Management scheduled to participate in Jones Trading AI/ML drug-development discussion.
May 18	First-quarter earnings report	Positive	+4.0%	Q1 results included $134.9 million in cash and operations funded into 2029.
May 12	Conference participation	Neutral	-1.4%	Management scheduled presentation at the 2026 Stifel Virtual Targeted Oncology Forum.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Conference and presentation announcements produced mixed reactions, ranging from -1.39% to 4.08% over the available history.

Key Terms

adaptive platform trial, bispecific antibody, anti-TIGIT antibody

3 terms

adaptive platform trial medical

"evaluated in a blinded randomized ovarian cancer adaptive platform trial"

An adaptive platform trial is a flexible clinical study design that tests multiple treatments at once and adjusts which drugs, doses, or patient groups are pursued as results come in. Think of it like a single kitchen testing several recipes and quickly favoring the ones that work while dropping or changing the others — this can speed development, cut costs, and reduce risk for investors by identifying winners and failures faster than traditional one-at-a-time trials.

bispecific antibody medical

"a PD-1/TIGIT bispecific antibody with a TIGIT component"

A bispecific antibody is a specially designed protein that can attach to two different targets at the same time. Think of it as a custom-made connector that brings two things together—such as a disease cell and an immune system component—helping the body fight illnesses more effectively. For investors, understanding bispecific antibodies is important because they represent innovative therapies that could lead to new treatments and potentially lucrative market opportunities.

anti-TIGIT antibody medical

"Compugen's anti-TIGIT antibody, is being developed by AstraZeneca"

A lab-made antibody that binds the immune receptor TIGIT to block an inhibitory signal on T cells and natural killer cells; by removing this “brake” the antibody aims to strengthen the immune system’s ability to attack cancer or other diseased cells. It matters to investors because clinical trial results, regulatory decisions, and commercial potential for these drugs can drive biotech valuations, partnerships, licensing deals, and future revenue prospects, much like progress on a new engine affects a carmaker’s outlook.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HOLON, Israel, July 21, 2026 /PRNewswire/ -- Compugen Ltd. (NASDAQ: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery powered by AI/ML, today announced that management will present and hold 1x1 meetings at the BTIG Biotechnology Conference 2026 taking place virtually from July 28-29, 2026.

Please reach out to your BTIG representative to request a meeting.

A replay for this event will not be available.

About Compugen

Compugen is a clinical-stage therapeutic discovery and development company utilizing Unigen™, its AI/ML powered computational discovery platform, to identify novel drug targets and to develop therapeutics in the field of cancer immunotherapies. Compugen's innovative immuno-oncology pipeline consists of COM701, rilvegostomig and GS-0321 (previously COM503). COM701, a potential first-in-class anti-PVRIG antibody, is currently being evaluated in a blinded randomized ovarian cancer adaptive platform trial as a single agent in maintenance therapy in relapsed platinum sensitive ovarian cancer (named MAIA-ovarian trial). Rilvegostomig, a PD-1/TIGIT bispecific antibody with a TIGIT component that is derived from COM902, Compugen's anti-TIGIT antibody, is being developed by AstraZeneca pursuant to an exclusive license agreement between Compugen and AstraZeneca and is being evaluated in multiple Phase 3, Phase 2 and Phase 1 clinical trials. GS-0321 (previously COM503), Compugen's potential first-in-class high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18, is licensed to Gilead and is being evaluated in a Phase 1 clinical trial that Compugen is conducting. In addition, Compugen has an early-stage immuno-oncology pipeline that consists of research programs aiming to address various mechanisms to enhance anti-cancer immunity. Compugen's shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.

Company Contact:

Lindsey Trickett
Head of Investor Relations and Corporate Communications
Email: lindseyt@cgen.com
Tel: +1 (628) 241-0071

 

View original content:https://www.prnewswire.com/news-releases/compugen-to-participate-in-btig-biotechnology-conference-2026-302830569.html

SOURCE Compugen Ltd.

FAQ

When will Compugen (CGEN) participate in the BTIG Biotechnology Conference 2026?

Compugen will participate in the virtual BTIG Biotechnology Conference 2026 from July 28-29, 2026. According to Compugen, company management will present and hold 1x1 meetings with investors during the two-day event.

How can investors schedule a 1x1 meeting with Compugen (CGEN) at the BTIG Biotechnology Conference 2026?

Investors can request a 1x1 meeting with Compugen by contacting their BTIG representative directly. According to Compugen, meeting requests and scheduling are handled through BTIG, and a replay of the event will not be available.

Will there be a replay of Compugen’s presentation at the BTIG Biotechnology Conference 2026 for CGEN shareholders?

No, a replay of Compugen’s BTIG Biotechnology Conference 2026 participation will not be available. According to Compugen, investors interested in the presentation or 1x1 meetings should coordinate in advance with their BTIG representative.

What cancer immunotherapy programs will Compugen (CGEN) highlight around the BTIG Biotechnology Conference 2026?

Compugen may highlight its immuno-oncology pipeline, including COM701, rilvegostomig, and GS-0321. According to Compugen, these programs are in clinical trials, with partnered assets licensed to AstraZeneca and Gilead under existing agreements.

What is Compugen’s clinical-stage cancer immunotherapy focus as CGEN attends the BTIG Biotechnology Conference 2026?

Compugen focuses on discovering and developing cancer immunotherapies using its Unigen AI/ML platform. According to Compugen, its pipeline targets mechanisms such as PVRIG, TIGIT, and IL-18 binding protein, aiming to enhance anti-cancer immune responses.

On which stock exchanges is Compugen (CGEN) listed as it joins the BTIG Biotechnology Conference 2026?

Compugen shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN. According to Compugen, this dual listing supports access for both U.S. and Israeli investors interested in its cancer immunotherapy pipeline.